<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17461" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Aminoglycosides</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Block</surname>
            <given-names>Megan</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Blanchard</surname>
            <given-names>Dana L.</given-names>
          </name>
          <aff>St. Joseph Mercy Hospital - Ann Arbor</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Megan Block declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dana Blanchard declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17461.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">While aminoglycosides are an older class of medication, they continue to be clinically valuable. Aminoglycosides have a broad spectrum of activity covering aerobic organisms, including gram-negative bacteria and mycobacteria. There are several drugs within the aminoglycoside class, including gentamicin, tobramycin, amikacin, neomycin, plazomicin, and streptomycin, and FDA-approved indications vary between the for these individual aminoglycosides. This activity reviews the indications, contraindications, mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent to members of the interprofessional team who wish to prescribe aminoglycosides.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of action of the aminoglycosides.</p></list-item><list-item><p>Outline the indications for different aminoglycosides.</p></list-item><list-item><p>Summarize the adverse effects and monitoring requirements of aminoglycosides.</p></list-item><list-item><p>Explain the importance of antimicrobial stewardship and how it affects antimicrobial selection as it pertains to improving care coordination among the interprofessional team when initiating aminoglycoside therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17461&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17461">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17461.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Although not a new class of antimicrobials, aminoglycosides have continued to prove their clinical value in fighting infections.&#x000a0;Aminoglycosides have a broad spectrum of activity covering aerobic organisms, including gram-negative bacteria and mycobacteria. Because there are several drugs within the aminoglycoside class, including gentamicin, tobramycin, amikacin, neomycin, plazomicin, paromomycin, and streptomycin, FDA approved indications vary between the different individual aminoglycosides.&#x000a0;&#x000a0;</p>
        <p>In general, indications for aminoglycosides include both empirical or directed treatment.&#x000a0;Since this drug class has demonstrated effectiveness in multi-drug resistant Gram-negative pathogens, aminoglycosides are indicated for empiric therapy in patients with severe illness; this includes empiric treatment for patients with infective endocarditis, sepsis, complicated intraabdominal infections, and complicated genitourinary infections. Typically, in these settings, aminoglycosides should not be used for more than two days, due to toxicity to the patient.&#x000a0;</p>
        <p>For directed treatment, aminoglycoside use for longer than 48 hours is acceptable. They are part of directed combination treatment for brucellosis, listeriosis, CNS nocardiosis, and <italic toggle="yes">Pseudomonas aeruginosa</italic> infection. Aminoglycosides monotherapy is for tularemia, resistant mycobacteria, bacteremia caused by <italic toggle="yes">Campylobacter</italic>
<italic toggle="yes">spp.</italic> and <italic toggle="yes">Yersinia spp.</italic>, and drug-resistant gram-negative pathogens. The Infectious Diseases Society of America Guidelines should be referenced to see if an aminoglycoside is the correct agent to use for a particular patient.<xref ref-type="bibr" rid="article-17461.r1">[1]</xref><xref ref-type="bibr" rid="article-17461.r2">[2]</xref></p>
      </sec>
      <sec id="article-17461.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Aminoglycosides have bactericidal activity in which they bind to the bacteria ribosomal 30S subunit. Specifically, they are believed to bind to the A-site (aminoacyl) on the 16S rRNA, a component of the ribosomal 30S subunit. Through this binding, the genetic code gets misread, and the translation is disrupted, leading to the bacteria being unable to carry out protein synthesis.<xref ref-type="bibr" rid="article-17461.r3">[3]</xref><xref ref-type="bibr" rid="article-17461.r4">[4]</xref></p>
      </sec>
      <sec id="article-17461.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Depending on the aminoglycoside chosen, the administration can be oral, parenteral, inhalation, intraperitoneal, or intraventricular. Administration of these agents is most commonly parenteral; gentamicin, amikacin, and tobramycin are the most frequently used aminoglycosides administered via the parenteral route.<xref ref-type="bibr" rid="article-17461.r1">[1]</xref> Tobramycin may be inhaled using a nebulizer for cystic fibrosis patients experiencing pulmonary exacerbation from infection.<xref ref-type="bibr" rid="article-17461.r5">[5]</xref>&#x000a0; Aminoglycosides taken orally are paromomycin and neomycin because they are not able to be absorbed systemically; these two aminoglycosides demonstrate&#x000a0;intraluminal activity in the bowel.&#x000a0; In addition,&#x000a0;gentamicin is&#x000a0;an aminoglycoside that can be administered intraperitoneally and intraventricularly. Intraperitoneal administration of gentamicin is useful in peritoneal dialysis patients who develop peritonitis.<xref ref-type="bibr" rid="article-17461.r6">[6]</xref> Gentamicin administration intraventricularly&#x000a0;has proved helpful in central nervous system infections.<xref ref-type="bibr" rid="article-17461.r7">[7]</xref></p>
      </sec>
      <sec id="article-17461.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The main noted adverse effects of aminoglycosides are ototoxicity, nephrotoxicity, and neuromuscular blockade.&#x000a0; Therefore, patients should be educated to look out for warning signs of these adverse effects before the initiation of aminoglycoside therapy.<xref ref-type="bibr" rid="article-17461.r1">[1]</xref></p>
        <p>Aminoglycoside-induced ototoxicity has been reported to occur in 2 to 45% of adults.&#x000a0; The ototoxicity can be vestibular and/or cochlear and is typically dose-dependent. Gentamicin, streptomycin, and tobramycin more commonly cause vestibular damage, while amikacin and kanamycin (discontinued use in the USA) result in more cochlear damage.<xref ref-type="bibr" rid="article-17461.r8">[8]</xref> Studies have found that aminoglycosides&#x000a0;seem to create reactive oxygen species within the inner ear; this, in turn, causes damage to the vestibular and cochlear sensory cells&#x000a0;along with cochlear neurons. Often the vestibular loss is salvageable while hearing loss is irreversible.<xref ref-type="bibr" rid="article-17461.r9">[9]</xref><xref ref-type="bibr" rid="article-17461.r10">[10]</xref></p>
        <p>Nephrotoxicity due to aminoglycosides may appear in up to 10 to 25% of patients.&#x000a0; In patients receiving aminoglycoside therapy, renal tubular toxicity decreased blood flow to the kidneys, and reduced GFR most commonly causes the nephrotoxicity seen.&#x000a0;Renal effects with aminoglycosides generally are reversible. Furthermore, there are risk factors associated with the development of aminoglycoside-induced nephrotoxicity, including dehydration, pregnancy, and hepatic dysfunction. Taking other medications concurrently with aminoglycosides that can cause nephrotoxicity, such as NSAIDs, cyclosporine, and diuretics, also puts a patient at risk for&#x000a0;renal problems.&#x000a0; It is important to monitor patient renal function when taking aminoglycosides.<xref ref-type="bibr" rid="article-17461.r11">[11]</xref><xref ref-type="bibr" rid="article-17461.r12">[12]</xref></p>
        <p>Aminoglycosides have also demonstrated correlations with neuromuscular blockade. Although this is less common than ototoxicity and nephrotoxicity, patients with diseases affecting the neuromuscular junction and patients using medications prolonging neuromuscular blockade, most notably calcium channel blockers, should be cautious when using aminoglycosides.<xref ref-type="bibr" rid="article-17461.r13">[13]</xref><xref ref-type="bibr" rid="article-17461.r14">[14]</xref></p>
      </sec>
      <sec id="article-17461.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Aminoglycosides should be avoided in patients with myasthenia gravis because of the risk of prolonged neuromuscular blockade.</p>
      </sec>
      <sec id="article-17461.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Therapeutic drug monitoring is necessary with aminoglycosides to optimize patient outcomes and limit toxicity. However, there is no universal agreement on the method of monitoring. Therapeutic drug monitoring has been shown to reduce hospital stay duration and toxicities. &#x000a0;Studies also suggest that therapeutic drug monitoring reduces mortality. It is important to note that monitoring clearance should be considered in critically ill, burn, and obese patients due to their abnormal distribution volume.<xref ref-type="bibr" rid="article-17461.r15">[15]</xref></p>
        <p>For toxicity purposes, renal function and cochlear function require monitoring. Serial audiometry may be considered to prevent irreversible hearing loss. Additionally, monitoring serum creatinine&#x000a0;must&#x000a0;be done to assess for nephrotoxicity in patients requiring aminoglycoside therapy.<xref ref-type="bibr" rid="article-17461.r9">[9]</xref><xref ref-type="bibr" rid="article-17461.r11">[11]</xref></p>
      </sec>
      <sec id="article-17461.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is no antidote for the toxicities of aminoglycosides. However, agents with protective effects on the ear and kidney may help prevent aminoglycoside-induced toxicity.&#x000a0; In particular, N-acetylcysteine demonstrates promising protective effects on patients using aminoglycosides.<xref ref-type="bibr" rid="article-17461.r16">[16]</xref></p>
      </sec>
      <sec id="article-17461.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Evaluating the need for aminoglycoside therapy&#x000a0;requires a holistic approach by an interprofessional team of professional individuals, including but not limited to physicians, specialists, nurses, pharmacists, laboratory technologists, audiometric technicians, and social workers, to achieve optimal outcomes. [Level V]</p>
        <p>Physicians and pharmacists have a critical role in determining the need for empiric treatment or directed treatment with an aminoglycoside.&#x000a0; Both healthcare professionals need to utilize communication and their expertise to determine if and which aminoglycoside is necessary, what is the correct dosing, and what is the optimal duration of therapy.&#x000a0; Therapeutic dose monitoring should also be done for the patient to achieve the best results with aminoglycoside treatment. In many institutions, the clinician initiates aminoglycoside therapy, and the clinical pharmacist handles all the dosing and subsequent adjustments, using kinetic dosing criteria. When in the hospital, nurses must assess for any potential toxicities developing in a patient. Because toxicity outcome typically depends on early detection, healthcare professionals need to monitor patients for any adverse signs and communicate with the team for the next step in therapy. Nurses will administer the drug and should be alert to signs of toxicity, interactions, and therapeutic effectiveness. Laboratory technologists and audiometric technicians are essential for checking serum creatinine in all patients and performing audiometry. Lastly, the role of a social worker is significant in preparing a patient for discharge while still on aminoglycoside therapy. All healthcare disciplines working as part of the interprofessional teams have their roles to play, making communication and collaboration key in providing patients with the best outcome care leading to optimal outcomes. [Level V]</p>
      </sec>
      <sec id="article-17461.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17461&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17461">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17461/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17461">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17461.s11">
        <title>References</title>
        <ref id="article-17461.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avent</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Paterson</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity.</article-title>
            <source>Intern Med J</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>441</fpage>
            <page-range>441-9</page-range>
            <pub-id pub-id-type="pmid">21309997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17461.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pagkalis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mantadakis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mavros</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Ammari</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Falagas</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological considerations for the proper clinical use of aminoglycosides.</article-title>
            <source>Drugs</source>
            <year>2011</year>
            <month>Dec</month>
            <day>03</day>
            <volume>71</volume>
            <issue>17</issue>
            <fpage>2277</fpage>
            <page-range>2277-94</page-range>
            <pub-id pub-id-type="pmid">22085385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17461.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kotra</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mobashery</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>12</issue>
            <fpage>3249</fpage>
            <page-range>3249-56</page-range>
            <pub-id pub-id-type="pmid">11083623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17461.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krause</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Serio</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Connolly</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Aminoglycosides: An Overview.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2016</year>
            <month>Jun</month>
            <day>01</day>
            <volume>6</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">27252397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17461.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rowbotham</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Charbek</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Oct</month>
            <day>30</day>
            <volume>10</volume>
            <issue>10</issue>
            <fpage>CD008319</fpage>
            <pub-id pub-id-type="pmid">30376155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17461.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ranganathan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Varghese</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Fassett</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Lipman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>D'Intini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Healy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study.</article-title>
            <source>BMC Nephrol</source>
            <year>2009</year>
            <month>Dec</month>
            <day>16</day>
            <volume>10</volume>
            <fpage>42</fpage>
            <pub-id pub-id-type="pmid">20003546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17461.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LeBras</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mabasa</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Ensom</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Systematic Review of Efficacy, Pharmacokinetics, and Administration of Intraventricular Aminoglycosides in Adults.</article-title>
            <source>Neurocrit Care</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>492</fpage>
            <page-range>492-507</page-range>
            <pub-id pub-id-type="pmid">27043949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17461.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leis</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rutka</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Aminoglycoside-induced ototoxicity.</article-title>
            <source>CMAJ</source>
            <year>2015</year>
            <month>Jan</month>
            <day>06</day>
            <volume>187</volume>
            <issue>1</issue>
            <fpage>E52</fpage>
            <pub-id pub-id-type="pmid">25225217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17461.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Selimoglu</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Aminoglycoside-induced ototoxicity.</article-title>
            <source>Curr Pharm Des</source>
            <year>2007</year>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>119</fpage>
            <page-range>119-26</page-range>
            <pub-id pub-id-type="pmid">17266591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17461.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guthrie</surname>
                <given-names>OW</given-names>
              </name>
            </person-group>
            <article-title>Aminoglycoside induced ototoxicity.</article-title>
            <source>Toxicology</source>
            <year>2008</year>
            <month>Jul</month>
            <day>30</day>
            <volume>249</volume>
            <issue>2-3</issue>
            <fpage>91</fpage>
            <page-range>91-6</page-range>
            <pub-id pub-id-type="pmid">18514377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17461.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wargo</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Aminoglycoside-induced nephrotoxicity.</article-title>
            <source>J Pharm Pract</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>573</fpage>
            <page-range>573-7</page-range>
            <pub-id pub-id-type="pmid">25199523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17461.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lopez-Novoa</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Quiros</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Vicente</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Morales</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Lopez-Hernandez</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view.</article-title>
            <source>Kidney Int</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>79</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-45</page-range>
            <pub-id pub-id-type="pmid">20861826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17461.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Del Pozo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Baeyens</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Effects of calcium channel blockers on neuromuscular blockade induced by aminoglycoside antibiotics.</article-title>
            <source>Eur J Pharmacol</source>
            <year>1986</year>
            <month>Aug</month>
            <day>22</day>
            <volume>128</volume>
            <issue>1-2</issue>
            <fpage>49</fpage>
            <page-range>49-54</page-range>
            <pub-id pub-id-type="pmid">3758187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17461.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barrons</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced neuromuscular blockade and myasthenia gravis.</article-title>
            <source>Pharmacotherapy</source>
            <year>1997</year>
            <season>Nov-Dec</season>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>1220</fpage>
            <page-range>1220-32</page-range>
            <pub-id pub-id-type="pmid">9399604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17461.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roberts</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Norris</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paterson</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic drug monitoring of antimicrobials.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-36</page-range>
            <pub-id pub-id-type="pmid">21831196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17461.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vural</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ko&#x000e7;yi&#x0011f;it</surname>
                <given-names>&#x00130;</given-names>
              </name>
              <name>
                <surname>&#x0015e;an</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ero&#x0011f;lu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ketenci</surname>
                <given-names>&#x00130;</given-names>
              </name>
              <name>
                <surname>&#x000dc;nal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tokg&#x000f6;z</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>&#x000dc;nl&#x000fc;</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Protective Effect of N-Acetylcysteine against Amikacin-Induced Ototoxicity in End-Stage Renal Disease: A Randomized Trial.</article-title>
            <source>Perit Dial Int</source>
            <year>2018</year>
            <season>Jan-Feb</season>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-62</page-range>
            <pub-id pub-id-type="pmid">29097487</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
